Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $4,083,675.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) CEO Marc N. Casper sold 7,500 shares of the stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $544.49, for a total value of $4,083,675.00. Following the completion of the transaction, the chief executive officer now directly owns 66,655 shares in the company, valued at approximately $36,292,980.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Thermo Fisher Scientific Stock Up 2.7 %

Shares of Thermo Fisher Scientific stock opened at $557.09 on Friday. The business’s 50 day simple moving average is $565.67 and its 200 day simple moving average is $545.12. Thermo Fisher Scientific Inc. has a 52-week low of $475.77 and a 52-week high of $618.35. The firm has a market cap of $214.72 billion, a PE ratio of 31.60, a P/E/G ratio of 1.83 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.48.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its earnings results on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.19 by $0.21. Thermo Fisher Scientific had a return on equity of 21.42% and a net margin of 15.47%. The business had revenue of $11.45 billion for the quarter, compared to analyst estimates of $10.41 billion. During the same quarter last year, the firm earned $6.54 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 7.0% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 14th. Shareholders of record on Wednesday, March 15th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 0.25%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend is Tuesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.81%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Thermo Fisher Scientific by 1.3% in the third quarter. Vanguard Group Inc. now owns 32,166,910 shares of the medical research company’s stock valued at $16,314,735,000 after purchasing an additional 406,844 shares in the last quarter. BlackRock Inc. grew its stake in Thermo Fisher Scientific by 0.8% in the third quarter. BlackRock Inc. now owns 30,689,762 shares of the medical research company’s stock valued at $15,565,540,000 after purchasing an additional 256,512 shares in the last quarter. State Street Corp boosted its stake in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. State Street Corp now owns 16,158,876 shares of the medical research company’s stock worth $8,200,398,000 after acquiring an additional 135,437 shares during the period. Morgan Stanley boosted its stake in shares of Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after acquiring an additional 1,764,312 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Thermo Fisher Scientific by 1.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,123,657 shares of the medical research company’s stock worth $5,024,306,000 after acquiring an additional 161,344 shares during the period. 85.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on TMO. Robert W. Baird cut their target price on Thermo Fisher Scientific from $710.00 to $693.00 in a research note on Thursday, February 2nd. Deutsche Bank Aktiengesellschaft initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, December 13th. They set a “buy” rating and a $620.00 price target on the stock. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating on the stock in a research report on Tuesday, January 3rd. Morgan Stanley raised their price target on Thermo Fisher Scientific from $613.00 to $670.00 and gave the stock an “overweight” rating in a research report on Thursday, February 2nd. Finally, Barclays raised their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock an “overweight” rating in a research report on Thursday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $647.00.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.